Surface-enhanced Raman Spectroscopy: A Potential Tool for Early Diabetes Type II Diagnosis

A new study from researchers at the University of Agriculture Faisalabad and University of Education in Faisalabad, Pakistan has shown that surface-enhanced Raman spectroscopy (SERS) could be a promising tool for the early diagnosis and screening of biochemical changes during diabetes type II. The study, published in the journal Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, utilized SERS to study low molecular weight fraction (LMWF) proteins in blood serum samples of diabetic type II patients (1). The researchers employed 50 kDa filter devices to centrifuge the serum samples into LMWF and higher molecular weight fractions (HMWF), and found that SERS could detect biomarkers for the disease in the LMWF.

Doctor Using Glucometer On Patient's Finger | Image Credit: © Andrey Popov - stock.adobe.com

The study is important because early diagnosis of diabetes type II is difficult due to the presence of large amounts of HMWF, which suppress the contribution of LMWF proteins to disease diagnosis. The disease biomarkers are found in the LMWF proteins. The researchers were able to identify prominent SERS bands at 725 cm⁻¹, 842 cm⁻¹, 1025 cm⁻¹, 959 cm⁻¹, and 1447 cm⁻¹, which correspond to small molecular weight proteins and helped to diagnose the disease at an early stage.

Small molecular weight proteins are potential biomarkers for the early diagnosis of type II diabetes. However, their contribution to disease diagnosis is often suppressed due to the presence of higher molecular weight fraction proteins in blood serum. Centrifugation of serum samples using 50 KDa filter devices produces two fractions, low molecular weight fraction and high molecular weight fraction, which can be studied separately. SERS can be employed to detect small molecular weight proteins and distinguish healthy and diseased samples.

In addition to identifying the biomarkers, the researchers used chemometric techniques, such as principal component analysis (PCA) and partial least square discriminant analysis (PLS-DA), to differentiate and classify blood serum samples. The researchers suggest that SERS can be employed for the early diagnosis and screening of biochemical changes during diabetes type II, which is a non-insulin-dependent diabetes and a major health problem worldwide. According to the International Diabetes Federation, an estimated 537 million individuals suffer from diabetes around the world, and the number is expected to rise to 783 million in 2045.

The long-term impact of diabetes type II can cause life-threatening complications and a reduction in life expectancy. The disease is usually diagnosed at later stages, causing many problems in treatment. Early diagnosis is critical for extending life, reducing complications, and improving treatment outcomes. The study shows that SERS has the potential to be an important tool for the early diagnosis of diabetes type II, which could improve the quality of life for those affected by this disease.

Reference

Ehsan, U.; Nawaz, H.; Majeed, M. I.; Rashid, N.; Iram; Ali, Z; Zulfiqar, A.; Tariq, A.; Shahbaz, M.; Meraj, L.; Naheed, I; Sadaf, N. Surface-enhanced Raman spectroscopy of centrifuged blood serum samples of diabetic type II patients by using 50KDa filter devices. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2023, 293, 1224. DOI: https://doi.org/10.1016/j.saa.2023.122457